Dihydroergotamine Injection

Major

Dihydroergotamine Injection Abametapir Increased exposure of CYP3A4 substrate Details Dihydroergotamine Injection Alefacept Decreased dihydroergotamine plasma concentrations Details Dihydroergotamine Injection Apalutamide Erleada Reduced CYP3A4 substrate exposure Details Dihydroergotamine Injection Aprepitant Aponvie Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Dihydroergotamine Injection Avacopan Tavneos Increased exposure to CYP3A4 substrate Details Dihydroergotamine Injection Azithromycin AzaSite An increased risk of acute ergot toxicity (ergotism) Details Dihydroergotamine Injection Belzutifan Welireg Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Dihydroergotamine Injection Berotralstat Orladeyo Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Dihydroergotamine Injection Carbamazepine Carbatrol Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Dihydroergotamine Injection Ciprofloxacin Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Clofazimine Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Clotrimazole Aardora Anti-Fungal Maximum Strength Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Conivaptan Vaprisol Increased CYP3A substrate exposure Details Dihydroergotamine Injection Crizotinib Xalkori Increased dihydroergotamine exposure Details Dihydroergotamine Injection Dabrafenib Tafinlar Reduced sensitive CYP3A4 substrate exposure Details Dihydroergotamine Injection Daridorexant Increased CYP3A4 substrate with NTI exposure Details Dihydroergotamine Injection Dexfenfluramine Serotonin syndrome (confusion, mental status changes, diaphoresis, tremor, myoclonus, shivering, hyperreflexia, hypertension) Details Dihydroergotamine Injection Diltiazem Cardizem Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Dronedarone Multaq Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Duvelisib Copiktra Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Elinzanetant Lynkuet Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Dihydroergotamine Injection Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Injection Enzalutamide Xtandi Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Dihydroergotamine Injection Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Dihydroergotamine Injection Fexinidazole An increased CYP3A4 substrate exposure Details Dihydroergotamine Injection Fluconazole Diflucan Increased plasma concentrations of ergot derivatives and increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Fluoxetine RECONCILE Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Fluvoxamine Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Fosnetupitant Increased exposure of CYP3A4 substrate Details Dihydroergotamine Injection Gepotidacin Blujepa Increased CYP3A4 substrate with NTI exposure Details Dihydroergotamine Injection Imatinib Gleevec Increased dihydroergotamine plasma concentrations and an increased risk of ergotism Details Dihydroergotamine Injection Isavuconazole Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Isavuconazonium Cresemba Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Ivacaftor Kalydeco Increased CYP3A substrate exposure Details Dihydroergotamine Injection Lanreotide Altered exposure to CYP3A4 substrate Details Dihydroergotamine Injection Lazertinib Lazcluze Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Dihydroergotamine Injection Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Dihydroergotamine Injection Lenacapavir Sunlenca Increased dihydroergotamine exposure Details Dihydroergotamine Injection Lorlatinib Lorbrena Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details